Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML
{{output}}
Introduction: The treatment landscape of chronic myeloid leukemia (CML) has evolved with the introduction of second- and third-generation tyrosine kinase inhibitors (TKIs), oCering potential advantages over imatinib. We analyzed ... ...
